Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 38 Women only

Uterus transplantation to help women with infertility

Official title: OPRTUNTI: Offering Potential for Reproduction Through Transplantation of Uterus iN the Treatment of Infertility

Run by Johns Hopkins University · NCT05646992 · Data updated 2026-11-12

This study is testing if transplanting a uterus from a living donor can help women who don't have a uterus become pregnant and have healthy babies.

More Infertility of Uterine Origin trials

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 38 Years
SexWomen only
Enrollment40 (estimated)
SponsorJohns Hopkins University
Academic / other
Drugs / interventionsradiation
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedMarch 1, 2023
Main results expectedFebruary 28, 2033
Study endsFebruary 28, 2043
Registry record updatedAugust 11, 2026
Trial IDNCT05646992 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are genotypic females aged 18-38 with uterine factor infertility who have a strong desire to become pregnant and have or are willing to create cryopreserved embryos.

Probably not a fit

Patients who do not have uterine factor infertility or those who are outside the age range of 18-38 years may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to treat uterine factor infertility through uterus transplantation from living donors to women who lack a uterus. The study involves multiple stages, including screening, in vitro fertilization (IVF), and embryo cryopreservation, followed by the surgical transplantation of the uterus. Participants will take immunosuppressive medications to maintain the health of the transplanted uterus, which is intended to be temporary, lasting about five years, after which the uterus will be removed following childbirth. The ultimate goal is to enable successful pregnancies and the birth of healthy children.

Why it matters

Potential benefit: If successful, this approach could provide women with uterine factor infertility the opportunity to experience pregnancy and childbirth.

How similar studies have gone: Other studies on uterus transplantation have shown promising results, indicating that this approach is gaining traction in the medical field.

Who can join: the full rules

Show full inclusion / exclusion criteria
INCLUSION CRITERIA -

Recipient Inclusion Criteria:

* Genotypic female of any race, color, or ethnicity.
* Uterine factor infertility.
* Aged 18-38 years at time of egg retrieval.
* Strong desire to undergo uterus transplant in order to become pregnant and give birth to a child.
* Embryo cryopreservation with embryos located at Johns Hopkins:

  * Has a minimum of 4-8 cryopreserved normal embryos following Preimplantation Genetic Screening (PGS-screening).

OR o Is willing to undergo egg retrieval, in vitro fertilization, and PGS-screening to cryopreserve a minimum of 4-8 normal embryos.

* Willingness to undergo embryo implantation after uterus transplantation to achieve pregnancy.
* In the opinion of the study team, makes a reasonable effort to identify and refer her own potential uterus donor to the study team.
* Completes the protocol informed consent form.
* Non-smoker, defined by having never smoked or having quit \>6 consecutive months prior to screening.
* No co-existing medical condition which, in the opinion of the study team, could affect the immunosuppression protocol, surgical procedure, or ability to be pregnant or bear a child. (See Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of uterus transplantation.)
* Negative serum pregnancy test.
* Blood type compatible with donor.
* Negative crossmatch with donor.
* Patient agrees to comply with the protocol and states a dedication to the treatment regime.
* Agrees to uterus explanation following birth of a child and or 5 years without successful pregnancy.

Donor Inclusion Criteria:

* Genotypic female with an intact uterus.
* Medical history includes known successful pregnancy (e.g., gravid uterus).
* Aged 25 - 65 years.
* Consents to uterus donation and required pre-donation screening.
* For females of child-bearing potential: Negative serum pregnancy test.
* Blood type compatible with recipient.
* Negative crossmatch with recipient.

Donor and Recipient Inclusion Criteria:

* USA citizen or equivalent.
* No co-existing psycho-social problems (i.e., alcoholism, drug abuse).
* BMI ≤35

  o A higher BMI may be accepted at the discretion of the study team.
* Negative for HIV at transplant.
* Negative for malignancy for past 5 years.

EXCLUSION CRITERIA-

Donor and Recipient Exclusion Criteria:

* Positive for any of the following conditions:

  * Insulin-dependent diabetes mellitus.
  * Untreated sepsis.
  * HIV (active or seropositive).
  * Active tuberculosis.
  * Active Hepatitis B infection.
  * Active Hepatitis C infection.
  * Viral encephalitis.
  * Toxoplasmosis.
  * Current/recent (within 3 months of donation/screening consent) IV drug abuse.
  * Significant cardiac disease
  * Significant vascular disease o
* Sensitized recipients with high levels (50%) of panel-reactive Human Leukocyte Antigens (HLA) antibodies.
* Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc.
* Mixed connective tissue diseases and collagen diseases that can result in poor wound healing after surgery.
* Severe neurologic deficits.
* Patients considered unsuitable per the consulted Psychiatric/Psychologic appraisal.
* A history of medical non-compliance.

Donor Only Exclusion Criteria:

* Previous injury to the uterus including giving birth by Cesarean section.
* History of radiation therapy to the abdominal area.
* Other medical conditions, as determined by the study physicians, that would preclude donation.

Recipient Only Exclusion Criteria:

• Conditions that, in the opinion of the study team, may expose the recipient to unacceptable risks under immunosuppressive treatment.

Where it's running

  • Johns Hopkins University School of Medicine
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Richard J Redett, MD — Johns Hopkins University
  • Study coordinator: Jane Littleton, CRNP, MSN
  • Email: jlittl38@jhmi.edu
  • Phone: 410-955-6875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.